- Home
- SLQT vs PVLA Comparison
SLQT vs PVLA Comparison
Compare SLQT & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLQT
- PVLA
- Stock Information
- Founded
- SLQT 1999
- PVLA 2015
- Country
- SLQT United States
- PVLA United States
- Employees
- SLQT N/A
- PVLA N/A
- Industry
- SLQT Specialty Insurers
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- SLQT Finance
- PVLA Health Care
- Exchange
- SLQT Nasdaq
- PVLA Nasdaq
- Market Cap
- SLQT 343.7M
- PVLA 285.2M
- IPO Year
- SLQT 2020
- PVLA N/A
- Fundamental
- Price
- SLQT $2.07
- PVLA $55.68
- Analyst Decision
- SLQT Hold
- PVLA Strong Buy
- Analyst Count
- SLQT 2
- PVLA 11
- Target Price
- SLQT $4.38
- PVLA $56.64
- AVG Volume (30 Days)
- SLQT 2.8M
- PVLA 132.8K
- Earning Date
- SLQT 11-03-2025
- PVLA 08-14-2025
- Dividend Yield
- SLQT N/A
- PVLA N/A
- EPS Growth
- SLQT N/A
- PVLA N/A
- EPS
- SLQT 0.01
- PVLA N/A
- Revenue
- SLQT $1,526,594,000.00
- PVLA N/A
- Revenue This Year
- SLQT $13.85
- PVLA N/A
- Revenue Next Year
- SLQT $13.64
- PVLA N/A
- P/E Ratio
- SLQT $155.28
- PVLA N/A
- Revenue Growth
- SLQT 15.50
- PVLA N/A
- 52 Week Low
- SLQT $1.62
- PVLA $11.17
- 52 Week High
- SLQT $6.86
- PVLA $58.22
- Technical
- Relative Strength Index (RSI)
- SLQT 45.92
- PVLA 68.11
- Support Level
- SLQT $2.01
- PVLA $49.81
- Resistance Level
- SLQT $2.77
- PVLA $56.77
- Average True Range (ATR)
- SLQT 0.19
- PVLA 4.42
- MACD
- SLQT -0.02
- PVLA -0.21
- Stochastic Oscillator
- SLQT 28.06
- PVLA 79.11
About SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.